Shares in Stratagene have fallen 23.3 percent over the past week, though the reason for the decline is unclear. The company's shares dropped 15.3 percent last Thursday alone — two days after it announced a settlement with Takara Bio related to PCR enzyme blends, and a day before molecular diagnostics partner Focus Diagnostics announced that it was being acquired by Quest Diagnostics (see Briefs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.